Virtual Library
Start Your Search
Claus Steppert
Author of
-
+
P66 - Tumor Biology and Systems Biology - Basic and Translational Science - Outcomes (ID 205)
- Event: WCLC 2020
- Type: Posters
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P66.03 - Unfavorable Survival of TTF-1- Negative Adenocarcinoma (ID 1956)
00:00 - 00:00 | Presenting Author(s): Claus Steppert
- Abstract
Introduction
Since the JMDB study pemetrexed/platinum combinations are the preferred choice in metastatic adenocarcinoma (AC). At WCLC 2016 we could demonstrate superior survival of TTF-1-positive AC compared to TTF-1- negatives. Posthoc analysis of the Pointbreak study suggested that carboplatinum/paclitaxel therapy may be more effective in TTF-1- negative AC. Since 2016 TTF-1 negative AC were preferably treated by carboplatinum/paclitaxel in our institution.
Methods
286 patients, 171m, 114f, aged 34 to 91, median 67 years with metastatic or locally advanced lung cancer not eligible for chemoradiation were retrospectively analyzed. 149 patients had TTF-1- positive AC treated by platinum/pemetrexed (group A), 36 TTF-1- negative AC treated by platinum/pemetrexed (group B), 30 TTF-1- negative AC treated by carboplatinum/paclitaxel (group C) and 70 squamous cell lung cancer treated by carboplatinum/paclitaxel (group D).
Results
Median overall survival was 14.7 months for group A, 5.8 months for group B, 8,3 months for group D and 9.3 months for group D. Due to the small numbers the difference between group B and C didn’t reach significance. Interestingly survival for squamous cell lung cancer was superior to TTF-1- negative AC.
Conclusion
TTF-1- negative AC seems to represent a different biology compared to the majority of TTF-1 positive ACs with worse prognosis compared even to squamous cell lung cancer.
